https://mindmedicinelaw.com/briefing/french-study-examines-psilocybin-from-red-light-holland-20260608-11131The Psychedelic Journalen2026-06-08T15:04:30.772947+00:00French Study Examines Psilocybin from Red Light Hollandpsilocybin research, French brain study, Red Light Holland, psychedelic trials, commercial suppliers, international research, brain effects, policy implications, neuroscience, clinical applicationshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-pilot-shows-promise-for-depression-20260608-11130The Psychedelic Journalen2026-06-08T15:04:21.191708+00:00Psychedelic Therapy Pilot Shows Promise for Depressionpsychedelic therapy, clinical depression, pilot trial, mental health treatment, psilocybin, serotonin receptors, treatment protocols, psychiatric research, safety and efficacy, regulatory considerationhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-adhd-neuroplasticity-insights-20260605-11119The Psychedelic Journalen2026-06-08T15:04:49.416717+00:00Psilocybin's Potential in ADHD: Neuroplasticity Insightspsilocybin, ADHD, neuroplasticity, prenatal stress, clinical trials, psychedelic research, mental health, neuroscience, therapeutic potentialhttps://mindmedicinelaw.com/briefing/cross-national-psychedelic-use-study-icps-findings-20260605-10743The Psychedelic Journalen2026-06-07T15:03:15.224139+00:00Cross-National Psychedelic Use Study: ICPS Findingspsychedelic use, ICPS study, psilocybin, LSD, MDMA, ketamine, clinical trials, therapeutic guidelines, adverse health effects, nonmedical usehttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-resistant-depression-a-systematic-review-20260605-10754The Psychedelic Journalen2026-06-07T15:03:07.270035+00:00Ketamine and Esketamine for Resistant Depression: A Systematic Reviewketamine, esketamine, treatment-resistant depression, rapid antidepressant effects, clinical trials, mental health policy, NMDA receptor antagonists, long-term safety, healthcare utilizationhttps://mindmedicinelaw.com/briefing/clearmind-medicine-s-cmnd-100-trial-insights-webinar-20260605-10196The Psychedelic Journalen2026-06-06T22:03:58.284018+00:00Clearmind Medicine's CMND-100 Trial Insights Webinarclearmind medicine, cmnd-100 trial, psychedelic research, clinical trials, meai compound, market strategies, therapeutic potential, regulatory hurdleshttps://mindmedicinelaw.com/briefing/epa-s-tsca-chemical-submissions-implications-for-psychedelics-20260605-10065The Psychedelic Journalen2026-06-06T22:03:52.251890+00:00EPA's TSCA Chemical Submissions: Implications for PsychedelicsEPA, TSCA, chemical regulation, psychedelic research, Premanufacture Notice, Significant New Use Notice, regulatory compliance, new chemical substances, market impact, safety assessmenthttps://mindmedicinelaw.com/briefing/therapeutic-alliance-in-psilocybin-therapy-for-depression-20260604-11055The Psychedelic Journalen2026-06-08T15:04:41.054969+00:00Therapeutic Alliance in Psilocybin Therapy for Depressiontherapeutic alliance, psilocybin therapy, treatment-resistant depression, ego dissolution, psychedelic therapy, clinical outcomes, psychotherapy integration, depression treatment, mental health, clinical trialshttps://mindmedicinelaw.com/briefing/case-reports-in-psychedelic-research-impact-and-implications-20260604-10128The Psychedelic Journalen2026-06-06T22:04:26.095008+00:00Case Reports in Psychedelic Research: Impact and Implicationscase reports, psychedelic research, evidence hierarchy, esketamine approval, FDA, adverse event reporting, clinical trials, medical literature, treatment advancements, anecdotal evidencehttps://mindmedicinelaw.com/briefing/case-reports-their-role-in-treatment-approvals-and-medicine-20260604-10132The Psychedelic Journalen2026-06-06T22:04:16.869654+00:00Case Reports: Their Role in Treatment Approvals and Medicinecase reports, FDA approvals, esketamine, treatment-resistant depression, medical advancements, evidence hierarchy, rare drug reactions, post-marketing surveillance, clinical trials, medical researchhttps://mindmedicinelaw.com/briefing/ketamine-assisted-couple-therapy-new-frontiers-explored-20260604-10084The Psychedelic Journalen2026-06-06T22:04:10.284829+00:00Ketamine-Assisted Couple Therapy: New Frontiers Exploredketamine-assisted psychotherapy, couple therapy, emotional expression, trust enhancement, psychedelic therapy, mental healthcare, therapeutic protocols, psychotherapy modalities, relational dysfunction, attachment processeshttps://mindmedicinelaw.com/briefing/challenges-in-euthanasia-for-mental-disorders-legal-and-ethical-complexities-20260604-10131The Psychedelic Journalen2026-06-06T22:04:04.117858+00:00Challenges in Euthanasia for Mental Disorders: Legal and Ethical Complexitieseuthanasia, assisted suicide, mental disorders, legal frameworks, bioethics, psychiatric evaluation, multidisciplinary approach, safeguard systems, decision-making capacity, international variabilityhttps://mindmedicinelaw.com/briefing/cannabis-cue-task-shows-no-neural-differences-across-cud-risk-groups-20260603-10086The Psychedelic Journalen2026-06-07T15:03:41.193426+00:00Cannabis Cue Task Shows No Neural Differences Across CUD-Risk Groupscannabis use disorder, neural differences, inhibitory control, prefrontal activation, CUDIT-R, functional near-infrared spectroscopy, behavioral tasks, diagnostic tools, clinical practice, neural adaptationshttps://mindmedicinelaw.com/briefing/ketogenic-therapy-in-anorexia-nervosa-promising-trial-results-20260603-10087The Psychedelic Journalen2026-06-07T15:03:32.875594+00:00Ketogenic Therapy in Anorexia Nervosa: Promising Trial Resultsketogenic therapy, anorexia nervosa, psychiatric disorder, eating disorder treatment, clinical trial, dietary intervention, symptom management, public health, neuroscience, feasibility studyhttps://mindmedicinelaw.com/briefing/bnst-activity-in-alcohol-abstinence-implications-for-aud-treatment-20260603-10136The Psychedelic Journalen2026-06-07T15:03:23.781723+00:00BNST Activity in Alcohol Abstinence: Implications for AUD TreatmentBNST activity, alcohol use disorder, AUD treatment, neurobiology, abstinence, aversion-resistant intake, dBNST, phenotype-specific adaptations, operant task, calcium transientshttps://mindmedicinelaw.com/briefing/gut-brain-axis-in-anxiety-and-depression-new-insights-20260602-10733The Psychedelic Journalen2026-06-07T15:03:51.475735+00:00Gut-Brain Axis in Anxiety and Depression: New Insightsgut-brain axis, anxiety disorders, depression, probiotics, dietary interventions, mental health, dysbiosis, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/nitrous-oxide-abuse-b12-deficiency-neuro-risks-20260528-10109The Psychedelic Journalen2026-06-07T22:04:13.481652+00:00Nitrous Oxide Abuse: B12 Deficiency & Neuro Risksnitrous oxide abuse, vitamin B12 deficiency, neurological damage, public health concern, recreational drug use, neurotoxicity, clinical intervention, myeloneuropathy, cognitive disorders